Four separate teal component forms in a grouped arrangement.

Our evidence assessments are specific to a combination, outcome, population, and formulation.

Read our grading method

KLOW stack

BPC-157 + TB-500 + GHK-Cu + KPV

What does KPV add to KLOW? Review the four-peptide stack, mouse intestinal-inflammation research, GLOW comparisons, and safety uncertainties.

Peptide stack
Written by

Recorded source check: 4 October 2026

Review and updates

Overview

KLOW is commonly described as BPC-157, TB-500, GHK-Cu, and KPV.[1] KPV research provides a biological rationale for investigating inflammation, but the cited experiments do not establish that this four-peptide blend treats a human condition.[2] The evidence therefore needs to be read at the level of the actual intervention and measured outcome. This guide separates findings about the individual ingredients from findings about the complete combination, and keeps unresolved questions about formulation, benefit, and safety visible.

Ingredients

  • BPC-157Read the injury-recovery and safety evidence.
  • TB-500Check the distinction between thymosin beta-4 and its fragments.
  • GHK-CuKeep topical and injectable research separate.
  • KPVA tripeptide studied in cells and mouse intestinal-inflammation models.

KPV means lysine–proline–valine. A 2008 study examined intestinal and immune cells plus two mouse colitis models. KPV reduced inflammatory signaling, and oral administration in mice improved measures of intestinal inflammation.[2] This is evidence about KPV under those experimental conditions. It is not a clinical trial of injected KLOW, and human cell lines are not the same as treatment studies in people.

Why combine them?

The naming distinction is the added KPV.[1] A fair effectiveness comparison would hold the other ingredients constant and test a defined patient outcome. The KPV study contains no GLOW-versus-KLOW group, so it does not answer which blend is better.[2] A proposed reason to combine ingredients is a research question rather than a demonstrated advantage. To support an added benefit, a study needs to compare the complete combination with relevant alternatives and measure outcomes that matter to the intended use.

Combination benefits

Mouse colitis is a model of intestinal inflammation, not a general measure of “gut health.” Route, disease model, and endpoints matter. A finding in that model cannot by itself establish benefit for human inflammatory bowel disease, digestive symptoms, or the microbiome.[2] For someone with persistent digestive symptoms, identifying the cause matters more than choosing a blend by its name. The ingredient guides below help distinguish the separate research questions.

Safety & interactions

FDA reports that it has not identified human exposure data for KPV drug products and lacks information needed to assess human harm.[3] Safety for the complete KLOW combination remains an unanswered question in the sources discussed here. A mechanistic rationale does not resolve that uncertainty. Interpret these observations alongside the study population, route, and length of follow-up. A report of an event does not by itself establish causation, while a study that reports few events cannot exclude uncommon or delayed harms.

Read the Medical Disclaimer.

Forms & dosing

No. It examined oral KPV in an animal model, not a four-ingredient human regimen.[2] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use. Adding KPV also changes the intervention being evaluated, rather than merely renaming an existing study regimen.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Selected findings and their main limitations. Open an outcome or source count for the complete assessment. Counts refer to cited documents, not necessarily independent studies.
Outcome, finding and study designEvidence certaintySources
Animal or cell researchIndirect cell and animal experiments.[2]

The study does not test the KLOW combination in humans.[2]

Main limitation: Experimental inflammatory outcomes are not established clinical benefits of a four-peptide blend.[2]

Context sourcesRegulatory safety assessment.[3]

FDA identifies a major human safety-information gap for KPV.[3]

Main limitation: A safety-information gap cannot establish that a combination is safe or quantify its risk.[3]

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

No study of this exact combination is available in this collection. The studies below concern individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.

IngredientPDF recordAntiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy
IngredientPDF recordBPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment
IngredientPDF recordBPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats
IngredientPDF recordBypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine
IngredientPDF recordCelecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
IngredientPDF recordClopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordComplex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats
IngredientPDF recordCounteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine
IngredientPDF recordEffect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
IngredientPDF recordEffects of BPC-157 and TB-500 on Achilles tendon healing
IngredientPDF recordEffects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short- Bowel Rats
IngredientPDF recordEndothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
IngredientPDF recordEsophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME
IngredientPDF recordFourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157
IngredientPDF recordImpact of pentadecapeptide BPC 157 on muscle healing
IngredientPDF recordIn relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro
IngredientPDF recordIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
IngredientPDF recordIntragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot
IngredientPDF recordModulatory effects of BPC 157 on vasomotor tone and the activation of Src‑Caveolin‑1‑endothelial nitric oxide synthase pathway
IngredientPDF recordNovel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy
IngredientPDF recordOccluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordOcclusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension
IngredientPDF recordOver-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157
IngredientPDF recordPentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine
IngredientPDF recordPentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
IngredientPDF recordPentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion
IngredientPDF recordPentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats
IngredientPDF recordPharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
IngredientPDF recordProtective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury
IngredientPDF recordProtective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
IngredientPDF recordProtective effects of pentadecapeptide BPC 157 on gastric ulcer in rats
IngredientPDF recordRobert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordSafety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
IngredientPDF recordSalutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
IngredientPDF recordStable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS
IngredientPDF recordStable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
IngredientPDF recordStable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights
IngredientPDF recordThe anti-nociceptive effect of BPC-157 on the incisional pain model in rats
IngredientPDF recordThe effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
IngredientPDF recordTherapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats
IngredientPDF recordTracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats
IngredientPDF record0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
IngredientPDF recordA first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
IngredientPDF recordAssociation of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study
IngredientPDF recordEctopic Expression of Human Thymosin β4 Confers Resistance to Legionella pneumophila during Pulmonary and Systemic Infection in Mice
IngredientPDF recordExpression and localisation of thymosin beta- 4 in the developing human early fetal heart
IngredientPDF recordGlobal Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma
IngredientPDF recordHypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure
IngredientPDF recordHypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4
IngredientPDF recordIdentifi cation of Thymosin β 4 as an effector of Hand1-mediated vascular development
IngredientPDF recordLocal Photorelease of Caged Thymosin β4 in Locomoting Keratocytes Causes Cell Turning
IngredientPDF recordModulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio: Possible implication in the regulation of actin dynamics
IngredientPDF recordPEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
IngredientPDF recordRGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
IngredientPDF recordRecombinant Human Thymosin β4 Attenuates Endotoxemia-Induced ALI and EAE by Suppressing Inflammatory and Oxidative Responses
IngredientPDF recordRecombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease
IngredientPDF recordRecombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection
IngredientPDF recordRecombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
IngredientPDF recordRecombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis
IngredientPDF recordReparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function
IngredientPDF recordSerum thymosin β4 levels in patients with hepatitis B virusrelated liver failure
IngredientPDF recordSignificance of Thymosin β4 and Implication of PINCH-1-ILK-α-Parvin (PIP) Complex in Human Dilated Cardiomyopathy
IngredientPDF recordStructural basis of actin sequestration by thymosin-β4: implications for WH2 proteins
IngredientPDF recordSynthesis of thymosin β4 by peritoneal macrophages and adherent spleen cells
IngredientPDF recordThe Control of Actin Nucleotide Exchange by Thymosin β4 and Profilin. A Potential Regulatory Mechanism for Actin Polymerization in Cells
IngredientPDF recordThymosin β4-Enhancing Therapeutic Efficacy of Human Adipose-Derived Stem Cells in Mouse Ischemic Hindlimb Model
IngredientPDF recordThymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis
IngredientPDF recordThymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice
IngredientPDF recordThymosin β4 Regulates Focal Adhesion Formation in Human Melanoma Cells and Affects Their Migration and Invasion
IngredientPDF recordThymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models
IngredientPDF recordThymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell–derived cardiomyocytes in a porcine model of acute myocardial infarction
IngredientPDF recordThymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells
IngredientPDF recordThymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction
IngredientPDF recordThymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF- κB signaling axis in APP/PS1 mice
IngredientPDF recordThymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing
IngredientPDF recordThymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells
IngredientPDF recordThymosin-β4 Regulates Motility and Metastasis of Malignant Mouse Fibrosarcoma Cells
IngredientPDF recordThymosin β4 (Fx peptide) is a potent regulator of actin polymerization in living cells
IngredientPDF recordThymosin β4: A ubiquitous peptide in rat and mouse tissues
IngredientPDF recordThymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids
IngredientPDF recordThymosin beta‑4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells
IngredientPDF recordThymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
IngredientPDF recordThymosin β4 Sequesters the Majority of G-actin in Resting Human Polymorphonuclear Leukocytes
IngredientPDF recordA Torilis japonica Extract–GHK-Cu Complex Attenuates Th2 Cytokines and Promotes Keratinocyte Recovery: A Potential Antioxidant Strategy for Atopic Dermatitis
IngredientPDF recordA gene expression signature of emphysemarelated lung destruction and its reversal by the tripeptide GHK
IngredientPDF recordAugmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu
IngredientPDF recordEfficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth
IngredientPDF recordEnhanced biological properties of collagen/chitosan‑coated poly(ε‑caprolactone) scaffold by surface modification with GHK‑Cu peptide and 58S bioglass
IngredientPDF recordExploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms
IngredientPDF recordGlycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway
IngredientPDF recordGlycyl-L-histidyl-L-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway
IngredientPDF recordGlycyl- l -histidyl- l -lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro
IngredientPDF recordHuman skin penetration of a copper tripeptide in vitro as a function of skin layer
IngredientPDF recordHuman skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy
IngredientPDF recordImproved laccase production by Trametes versicolor using Copper-Glycyl-L-Histidyl-L-Lysine as a novel and high-efficient inducer
IngredientPDF recordIn Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer
IngredientPDF recordIn Vivo Stimulation of Connective Tissue Accumulation by the Tripeptide-Copper Complex Glycyl-L-histidyl-L-lysine-Cu2+ in Rat Experimental Wounds
IngredientPDF recordLiposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application
IngredientPDF recordMass spectral and theoretical investigations of the transient proton-bound dimers on the cleavage processes of the peptide GHK and its analogues
IngredientPDF recordMiddle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs
IngredientPDF recordThe Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline
IngredientPDF recordThe Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds
IngredientPDF recordThe copper(II)-binding tripeptide GHK, a valuable crystallization and phasing tag for macromolecular crystallography
IngredientPDF recordThe glycyl-l-histidyl-l-lysine-Cu2+ tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6
IngredientPDF recordThe naturally occurring peptide GHK reverses age-related fibrosis by modulating myofibroblast function
IngredientPDF recordThe tri-peptide GHK-Cu complex ameliorates lipopolysaccharideinduced acute lung injury in mice
IngredientPDF recordCritical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model
IngredientPDF recordStructural modification of the tripeptide KPV by reductive “glycoalkylation” of the lysine residue

FAQs

What is in KLOW?
Quick answer:

The name commonly covers the Wolverine pair plus GHK-Cu and KPV. Formulation details still need to be checked.[1] The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.

Has KLOW been shown to treat inflammatory bowel disease?
Quick answer:

The cited KPV paper studied cells and mice, not people receiving KLOW. It cannot establish treatment benefit for human inflammatory bowel disease.[2] The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others. The comparison must also preserve the population and outcome being discussed; a different intervention would need its own assessment.

How should I compare KLOW with GLOW?
Quick answer:

Start with a specific outcome, then ask whether the exact combination and route were studied against a relevant comparator. Ingredient count is not an evidence grade. The relevant question is whether the measured outcome matches the benefit being claimed. Changes in symptoms, laboratory measurements, and physical function answer different questions, so evidence for one should not silently become evidence for the others.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for KLOW stack.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

3 sources
  1. GLOW vs KLOW vs Wolverine Stack: Which One? — naming reference only (2026)Commercial description · Names and ingredients only
  2. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (2008)Primary research · Cells and miceReview status · PendingSave study
  3. FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Accessed 2026-10-04)Regulatory assessmentSave study